The data, which appeared in the online edition of Nature, "demonstrate that RNAi can occur in a human from a systemically delivered siRNA, and that siRNA can be used as a gene-specific therapeutic," the investigators wrote.
The program is designed to support the collection and analysis of "informative molecular activity and cellular feature signatures" in response to siRNAs, small molecules, and other perturbing agents in a variety of cell types.
Although Quark initially expects to market the drug as a treatment for a rare condition known as non-arteritic anterior ischemic optic neuropathy, it hopes it can eventually develop it as a glaucoma treatment.
Alnylam previously released data from a phase IIa study of the drug in RSV-infected adult lung transplant patients showing that it was safe and well tolerated. While the data indicated a certain level of efficacy, this demonstration was less robust than many industry watchers had expected.
The company's core technology is dubbed PRINT, or Pattern Replication In Non-wetting Templates. It involves making templates of specific patterns, on which a proprietary non-stick polymer is applied to create a mold.
The collaboration will focus on Bioo's Targeted Transport Technology, which involves joining a carrier agent to a monoclonal antibody to produce a conjugate that is then loaded with an RNAi molecule such as an siRNA or miRNA mimic, to deliver anti-HIV siRNAs into T cells.